KRRO:NASDAQKorro Bio, Inc. analysis
Data as of Sep 30, 2026 - not real-time
- Latest price
- $9.56
- Risk: high
- 9/10High risk
Summary
Korro Bio, Inc. is priced at $9.56, and its moving averages give no clean directional read — the structure is neutral. It has lost 27.2% over the past 30 days. With RSI at 32.3 the momentum picture is approaching oversold, alongside a bearish MACD signal. Watch $9.24 as support and $15.15 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 111.3% above where the shares trade now.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 86.9%, a beta of 2.68 and a maximum drawdown of 89.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 111.3% above where the shares trade now.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 86.9%, a beta of 2.68 and a maximum drawdown of 89.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Top market events
- KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence...
- CAMBRIDGE, Mass., Sept. 11, 2026 GLOBE NEWSWIRE -- Korro Bio, Inc. Korro Nasdaq: KRRO , a biopharmaceutical company...
- Yahoo Finance18dKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635 c 4 The above button links to...
Market outlook
Short term
< 1 yearNeutral
Model confidence2/102 out of 10
Key factors
- Trading below the 200-day average of 11.67
- MACD momentum is negative
- 30-day price change of -27.2%
Medium term
1–3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Trading below the 200-day average of 11.67
- Analyst targets imply +111.3% versus the current price
- 30-day volatility of 86.9%
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +111.3% versus the current price
- Negative return on equity of -97.7%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-2.1
ROE-97.69%
ROA-27.95%
Debt/Equity40.89
P/B Ratio1.4
Op. Cash Flow$-67948000
Free Cash Flow$-41390124
Industry P/E30.5
Technical analysis
TrendNeutral
RSI32.3
Support$9.24
Resistance$15.15
MA 20$11.67
MA 50$12.05
MA 200$11.67
MACDBearish
VolumeIncreasing
Fear & Greed Index92.79
Valuation
Target Price$20.20
Upside/Downside111.30%
GradeFair
TypeBlend
Risk assessment
Beta2.68
Volatility86.94%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.